Although GEMOX treatment is limited to pancreatic cancers with BRCA1/2 or PABL2 mutations according to the NCCN, it resulted in similar PFS and OS as the other two regimens in unselected Chinese patients. The gene discussed is BRCA1; the disease is familial pancreatic carcinoma.